A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma
Comparative Effectiveness of Elranatamab Monotherapy in the MagnetisMM-5 Clinical Trial Versus a Real-World External Control Arm of Patients With Relapsed/Refractory Multiple Myeloma With Prior Treatment of Lenalidomide and Proteasome Inhibitor From the Therapy Monitor Multiple Myeloma Dataset in Germany (BasecaMMp)
This study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again (known as relapsed refractory). This study medicine will be compared with standard-of-care (SOC) therapies used in real-world clinical practice. For people receiving elranatamab, we will use data from the phase 3 clinical trial (MagnetisMM-5). We will also use data from a real-world database, representing the SOC in clinical practice. This study does not seek any participants for enrollment. We will compare the experiences of people receiving elranatamab to people receiving SOC therapies. This way, it will help us to know how well elranatamab can be used for RRMM treatment.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Comparative effectiveness of elranatamab monotherapy in the MagnetisMM-5 clinical trial versus a real-world external control arm of patients with relapsed/refractory multiple myeloma with prior treatment of lenalidomide and proteasome inhibitor from the Therapy Monitor Multiple Myeloma dataset in Germany (BasecaMMp)
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Pfizer CT.gov Call Center
- Telefonnummer: 1-800-718-1021
- E-post: ClinicalTrials.gov_Inquiries@pfizer.com
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Patients treated with elranatamab will come from the MagnetisMM-5 trial. Patients treated with the standard-of-care therapies will come from electronic health record databases in Germany.
Beskrivning
To maximize comparability, the eligibility criteria for the participants from MagnetisMM-5 trial will be applied to patients from the RWD source, as feasible.
Inclusion Criteria:
- Male or Female aged 18 years and older at index date
- Diagnosis of MM
- Measurable disease according to IMWG criteria
- Prior anti-MM therapy (1-3 prior lines of therapy)
- ECOG performance status ≤2
Exclusion Criteria:
- Acute plasma cell leukemia
- Amyloidosis
- Smoldering MM
- Stem cell transplant within 12 weeks of index or active graft versus host disease (GVHD)
- Ongoing Grade 2 or higher peripheral sensory or motor neuropathy.
- Active systemic infection or SARS-CoV-2 viral infection
- Active malignancy within 3 years before index, except for basal cell or squamous cell skin cancer or carcinoma in situ
- Other surgical, medical, or psychiatric conditions including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
- Previous treatment with a BCMA-directed therapy or a CD3-redirecting therapy.
- Anti-CD38-directed therapy within 6 months preceding the first dose of treatment in this study
- Refractory to prior anti-CD38-directed therapy (disease progression while on or within 60 days of the last dose of any anti-CD38-directed therapy or failure to achieve at least MR).
- Previous pomalidomide therapy
- Administration with an investigational drug within 30 days prior to index
- For women of childbearing potential: Pregnancy test positive at screening
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: RETROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Elranatamab
Patients treated with elranatamab from the MagnetisMM-5 trial |
BCMA-CD3 bispecific antibody |
|
Standard of care
Patients treated with standard-of-care therapies from real-world data source |
Standard of Care |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Real World Progression Free Survival (rwPFS)
Tidsram: From the index date through the end of the study period, approximately 6 months.
|
From the index date through the end of the study period, approximately 6 months.
|
|
Overall Survival (OS)
Tidsram: From the index date through the end of the study period, approximately 6 months.
|
From the index date through the end of the study period, approximately 6 months.
|
|
Time to next treatment (TTNT)
Tidsram: From the index date through the end of the study period, approximately 6 months.
|
From the index date through the end of the study period, approximately 6 months.
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Pfizer CT.gov Call Center, Pfizer
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Kärlsjukdomar
- Hjärt-kärlsjukdomar
- Neoplasmer
- Immunsystemets sjukdomar
- Neoplasmer efter histologisk typ
- Hematologiska sjukdomar
- Lymfoproliferativa störningar
- Immunproliferativa störningar
- Hemostatiska störningar
- Paraproteinemier
- Blodproteinstörningar
- Hemorragiska störningar
- Hemiska och lymfsjukdomar
- Multipelt myelom
- Neoplasmer, Plasmacell
- Administration
- Sjukvårdskvalitet, tillgång och utvärdering
- Hälsovårdskvalitet
- Kvalitetsindikatorer, hälsovård
- Vårdstandard
Andra studie-ID-nummer
- C1071056
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .